StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
VBI Vaccines Price Performance
NASDAQ VBIV opened at $0.02 on Monday. VBI Vaccines has a twelve month low of $0.06 and a twelve month high of $1.35. The stock has a 50-day moving average of $0.25 and a 200 day moving average of $0.49.
VBI Vaccines Company Profile
Further Reading
- Five stocks we like better than VBI Vaccines
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3 Leveraged ETFs to Multiply Returns
- The Role Economic Reports Play in a Successful Investment Strategy
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.